JUST LAUNCHED
The Prosigna Breast ROR Test Now Available for Providers to Order in the US*
Your ally in the race against cancer
Transform uncertainty into clarity with Veracyte cancer tests
Our high-performing molecular tests empower clinicians and their patients with important information that has helped guide care decisions for over 900,000 people.1
How we help guide cancer care
Our tests assess the unique biology of each patient’s tumor. This helps clinicians answer key questions and make confident decisions for thyroid, prostate, breast, bladder, and lung cancer. The important information from our tests helps enable personalized and effective patient care.
We’re here to support your journey
Find the information most relevant to you.
Market-leading cancer tests backed by evidence1
>900K
Patients benefited from our genomic tests across multiple cancer types
>600
Peer-reviewed publications validate our platform’s clinical utility
>35
Phase 2 & 3 trials evaluating our tests
Did You Know?
Decipher Prostate Genomic Classifier
is the only gene expression test included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for prostate cancer2
Real impact on patient care
I knew there was another genomic test that could provide this information, but I specifically requested the Prosigna test because I wanted to be sure of the accuracy for guiding my treatment decisions.”1
The Afirma test saved me from a big change in my life and the joy of what I have gotten to keep is to continue having music in my life, to continue teaching at the highest level I can, which is to be able to use my voice when I’m teaching. The Afirma test was like a safety net, and I can go on with my life.”1
Veracyte Diagnostics Platform
A powerful evidence-generation engine that delivers diagnostic innovation.
More data
Transcriptomes, genomes, complementary data sources, and clinical outcomes
More utility
For current tests and new cancer applications
More evidence
From the analysis of real-world data and clinical studies
More insights
From AI-assisted data mining, multimodal analysis, and bioinformatics analysis
Veracyte Diagnostics Platform
Latest from Veracyte
Every breakthrough brings us closer to improved outcomes for those touched by cancer. Explore our latest updates, news, and insights.
Meet #TeamVeracyte, making a difference for patients globally
We value a diverse, inclusive workplace where creativity, collaboration, and compassion thrive. Our team members are empowered to lead discoveries that are changing the future of cancer care, with positions in state-of-the-art labs, offices, field locations, and remote work.
Let’s connect
References
- Veracyte, Inc. Company data on file, June 2026.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed March 12, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.
Disclaimers
* Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.
Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.